Comparing the current results to its competitors, Taysha Gene Therapies Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, slower than the combined decrease of the TSHA's competitors by -45.98 %, recorded in the same quarter.
May 2, 2024
In the pursuit of finding effective treatments for Rett Syndrome, Taysha Gene Therapies has achieved a significant milestone. The company recently announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for their therapy candidate, TSHA-102. This designation follows the FDA s review of safety and efficacy data from the initial three patients who were administered a low dosage of TSHA-102. Moreover, Taysha Gene Therapies has expanded the clinical evaluation of TSHA-102 to include both pediatric and adolescent/adult patients in their REVEAL Phase 1/2 trials.Expanding the Trial Eligibility for Pediatric Patients:One notable development is ...
November 29, 2023
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial for Rett Syndrome Patients, Including Adolescents Health Canada has authorized Taysha Gene Therapies protocol amendment to expand eligibility for the REVEAL Phase 1/2 adult trial in Canada. This expansion now includes patients aged 12 and older with stage four Rett syndrome. This development represents a significant step forward in addressing the healthcare needs of adolescents with this rare genetic disorder. Rett syndrome is a severe neurodevelopmental disorder that predominantly affects females. It is characterized by a loss of purposeful hand skills, cognitive impairment, and a variety of neurological and physic...
4D Molecular Therapeutics Inc operates with a business model focused on developing innovative gene therapy products to address serious genetic diseases. The company utilizes its proprietary technology platform to design and optimize viral vectors for targeted gene delivery. With a strong commitment to research and development, 4D Molecular Therapeutics collaborates with partners in academia, industry, and patient organizations to advance transformative treatments for patients in need.
Editas Medicine Inc.'s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its CRISPR/Cas9 gene-editing platform. They aim to leverage the potential of CRISPR to treat severe genetic diseases by directly modifying genes within the body's cells. The company collaborates with partners, conducts research and development of their therapeutics, and ultimately aims to bring their innovative treatments to market.
Cargo Therapeutics Inc is a biotechnology company that utilizes a unique business model focused on developing targeted therapeutics. Their approach involves engineering cell-penetrating peptides to deliver various cargoes, such as gene therapies or small molecules, directly to specific cells or tissues, increasing precision and effectiveness of treatments. By leveraging this technology, the company aims to address unmet medical needs with potentially transformative therapies.
Sources:
Taysha Gene Therapies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Taysha Gene Therapies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
